Exploring 2-methyl-substituted vitamin K 3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2

• Published in: Bioorganic & medicinal chemistry letters Vol. 100; p. 129642
• Main Authors: Koharazawa, Ryohto, Hayakawa, Mayu, Takeda, Kazuki, Miyazaki, Kotone, Tode, Chisato, Hirota, Yoshihisa, Suhara, Yoshitomo
• Format: Journal Article
• Language: English
• Published: England 02.02.2024
• ISSN: 1464-3405

Since the outbreak of the pandemic, various anti-SARS-CoV-2 drugs have been developed. In particular, 3CL protease (3C-like protease, 3CLpro) is an attractive drug target because it is an essential enzyme for viral multiplication and is present only in viruses, not in humans. To date, 3CLpro inhibitors against SARS-CoV-2 such as nirmatrelvir and ensitrelvir have been launched as oral drugs in Japan, but there is still no potent drug against SARS-CoV-2, due to issues of in vivo absorption and stability. Recently, vitamin K was reported to show inhibitory activity against 3CLpro of SARS-CoV-2, and the mechanism of action was predicted to be the formation of a covalent bond between the thiol group of cysteine 145, the active center of 3CLpro, and the C-3 position of vitamin K . Therefore, we synthesized derivatives in which the 2-methyl group of the vitamin K was systematically converted to other substituents and examined their inhibitory activity against 3CLpro of SARS-CoV-2. The results showed that the compounds with the sulfide structure showed an approximately 4-fold increase in activity over vitamin K . These results indicated the possibility of creating new inhibitors based on vitamin K and its derivatives.